These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34151695)

  • 1. Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry.
    Oosterhaven JAF; Spekhorst LS; Zhang J; Voorberg AN; Romeijn GLE; Boesjes CM; de Graaf M; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatolog Treat; 2022 Jun; 33(4):1986-1989. PubMed ID: 34151695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.
    Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA
    Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.
    Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    Contact Dermatitis; 2022 Aug; 87(2):185-191. PubMed ID: 35279856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spanish Version of the RECAP Questionnaire to Assess Control of Atopic Eczema: Translation, Cultural Adaptation, Validation, and Correlations with Other Patient-Reported Outcome Measures.
    Onteniente-Gomis MM; Ortiz-Romero PL; Tous Romero F; Salamanca Castro AB; Ortiz de Frutos FJ
    Actas Dermosifiliogr; 2023 Jun; 114(6):488-493. PubMed ID: 36935038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children.
    Ragamin A; Zhang J; Pasmans SGMA; Schappin R; Romeijn GLE; van Reusel MA; Oosterhaven JAF; Schuttelaar MLA
    Br J Dermatol; 2024 May; 190(6):867-875. PubMed ID: 38262143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
    Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
    Clabbers J; Boesjes C; Spekhorst L; van Gisbergen MW; Maas E; Marshall J; Janssen R; Janssen M; Zuithoff N; Steijlen P; de Graaf M; van Geel M; de Bruin-Weller M; Gostyński A
    J Allergy Clin Immunol; 2024 Apr; 153(4):1155-1161.e4. PubMed ID: 38272373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden, Control, and Treatment of Moderate to Severe Atopic Dermatitis in 2021: A United States Patient Survey Study.
    Lio P; Mackie D; Bates D; Mulvihill E; Patel M; Kim Y; Shi V
    J Drugs Dermatol; 2023 Feb; 22(2):119-131. PubMed ID: 36745377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
    Spekhorst LS; de Graaf M; Loeff F; Zuithoff NPA; Bakker D; Boesjes CM; Thijs J; Achten R; van Wijk F; Rispens T; de Bruin-Weller MS
    JAMA Dermatol; 2022 Dec; 158(12):1409-1413. PubMed ID: 36322072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
    Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
    de Wijs LEM; Bosma AL; Erler NS; Hollestein LM; Gerbens LAA; Middelkamp-Hup MA; Kunkeler ACM; Nijsten TEC; Spuls PI; Hijnen DJ
    Br J Dermatol; 2020 Feb; 182(2):418-426. PubMed ID: 31145810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis.
    Simpson E; Eckert L; Gadkari A; Mallya UG; Yang M; Nelson L; Brown M; Reaney M; Mahajan P; Guillemin I; Boguniewicz M; Pariser D
    BMC Dermatol; 2019 Nov; 19(1):15. PubMed ID: 31690295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
    Zhang J; Ragamin A; Romeijn GLE; Loman L; Oosterhaven JAF; Schuttelaar MLA
    Br J Dermatol; 2023 Oct; 189(5):578-587. PubMed ID: 37463409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.
    Strober B; Mallya UG; Yang M; Ganguli S; Gadkari A; Wang J; Sierka D; Delevry D; Kimball AB
    JAMA Dermatol; 2022 Feb; 158(2):142-150. PubMed ID: 34910086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
    Spekhorst LS; de Graaf M; Zuithoff NPA; van den Reek JMPA; Kamsteeg M; Boesjes CM; Romeijn GLE; Loman L; Haeck I; Oosting AJ; de Boer-Brand A; Touwslager WRH; Flinterman A; van Lynden-van Nes AMT; Gostynski AH; de Bruin-Weller MS; Schuttelaar ML
    JAMA Dermatol; 2022 Sep; 158(9):1048-1056. PubMed ID: 35947364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
    Kamphuis E; Boesjes CM; Loman L; Kamsteeg M; Haeck I; Van Lynden-van Nes AMT; Politiek K; Van der Gang LF; De Graaf M; De Bruin-Weller MS; Schuttelaar MLA
    Acta Derm Venereol; 2024 Feb; 104():adv19454. PubMed ID: 38323500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
    Ariëns LFM; Bakker DS; Spekhorst LS; Van der Schaft J; Thijs JL; Haeck I; Flinterman AE; Kamsteeg M; Schuttelaar MLA; De Bruin-Weller MS
    Acta Derm Venereol; 2021 Oct; 101(10):adv00573. PubMed ID: 34396421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
    Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
    Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.